We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
216 result(s) found, displaying 21 to 30
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Malaysia Intragam NexGen MY normal immunoglobulin (human) 5g 100 g/L, 10% solution for intravenous infusion.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Malaysia Albumex 20 NexGen MY, Solution for infusion 20%.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL NZ Alburex 5 NZ human albumin 50 g/L (5% w/v) solution for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Taiwan PRIVIGEN TW normal immunoglobulin (human) 5g (100g/L,10%) solution for intravenous infusion.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Hong Kong Intragam NexGen HK normal immunoglobulin (human) 5g 100 g/L, 10% solution for intravenous infusion.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HEMGENIX etranacogene dezaparvovec 1 unit solution for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Taiwan AlbuRx 20 TW human albumin 200g/L (20% w/v) solution for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Hong Kong Albumex 20 NexGen Human Albumin 200g/L Solution for Intravenous Infusion.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL New Zealand Alburex 20 NZ, Solution for infusion 20%.
-
Australian public assessment report (AusPar)Hemgenix (etranacogene dezaparvovec), a gene therapy, has been approved for the treatment of haemophilia B (congenital factor IX deficiency) in adults.